Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Purity: ≥98%
Elimusertib (BAY1895344) HCl, the hydrochloride salt of BAY 1895344, is a selective and orally bioavailable ATR (ataxia telangiectasia and Rad3-related) inhibitor with potential antitumor activity. It suppresses ATR with an IC50 of 7 nM.
Targets |
ATR ( IC50 = 7 nM )
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Enzyme Assay |
Elimusertib (BAY1895344) has an IC50 of 7 nM, which inhibits ATR.
|
|
Cell Assay |
BAY 1895344 inhibits the phosphorylation of H2AX induced by hydroxyurea in cellular mechanistic assays. BAY 1895344 significantly suppresses hydroxyurea-induced H2AX phosphorylation in cellular mechanistic assays (IC50=36 nM).
|
|
Animal Protocol |
Female C.B-17 SCID mice, SU-DHL-8 GCB-DLBCL xenograft model
50 mg/kg Oral administration, b.i.d., 3 days on/4 days off, for 11 days |
|
References |
|
Molecular Formula |
C20H22CLN7O
|
|
---|---|---|
Exact Mass |
411.16
|
|
Elemental Analysis |
C, 58.32; H, 5.38; Cl, 8.61; N, 23.80; O, 3.88
|
|
Related CAS # |
1876467-74-1
|
|
Appearance |
Yellow solid powder
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05071209 | Active Recruiting |
Drug: Elimusertib | Recurrent Lymphoma Refractory Lymphoma |
National Cancer Institute (NCI) |
December 22, 2021 | Phase 1 Phase 2 |
NCT04267939 | Active Recruiting |
Drug: Elimusertib (BAY1895344) Drug: Niraparib |
Advanced Ovarian Carcinoma Advanced Fallopian Tube Carcinoma |
Bayer | February 26, 2020 | Phase 1 |
NCT04491942 | Recruiting | Drug: Elimusertib Drug: Cisplatin |
Advanced Gastric Carcinoma Advanced Penile Carcinoma |
National Cancer Institute (NCI) |
August 25, 2021 | Phase 1 |
NCT03188965 | Completed | Drug: Elimusertib (BAY1895344) |
Advanced Solid Tumor Mantle Cell Lymphoma |
Bayer | July 6, 2017 | Phase 1 |